文献速递妇科

2010至2013年美国私人保险女性盆腔器官脱垂手术率分析

Rate of Pelvic Organ Prolapse Surgery Among Privately Insured Women in the United States, 2010-2013.
PubMed 文献 · Obstet Gynecol · 2018-01-01

该回顾性队列研究分析2010至2013年三家保险机构的私人理赔数据,发现盆腔器官脱垂手术利用率从每万女性年12.3降至9.7(P=.027);2011年FDA关于经阴道网片的沟通后,网片手术利用率显著下降,非网片手术无显著变化;住院手术减少而门诊手术增加,单次手术支付费用上升。

要点

  • 脱垂手术总利用率从2010年12.3/万女性年降至2013年9.7/万女性年(P=.027)。
  • FDA沟通后网片手术季度利用率斜率由0.024转为-0.025(P=.002),非网片手术下降不显著(P=.47)。
  • 住院脱垂手术利用率下降52.2%(P=.002),门诊手术利用率上升18.5%(P=.132)。

核心结论

  • 研究期间盆腔器官脱垂手术使用率下降;2011年FDA关于经阴道网片的沟通后,网片手术利用率显著下降,非网片手术无显著变化;观察到向门诊手术转移,住院和门诊单次手术支付费用均增加。

研究设计与样本

  • 回顾性队列研究,分析Health Care Cost Institute中三家保险机构2010至2013年住院和门诊脱垂手术的私人理赔数据。

主要发现

  • 脱垂手术总利用率从每万女性年12.3降至9.7(P=.027)。
  • 网片手术数量从2010年3.9降至2013年2.7,降幅30.7%(P=.05);非网片手术从8.4降至7.0,降幅16.6%(P=.011)。
  • 网片手术季度利用率在FDA沟通前上升、沟通后显著下降(斜率0.024 vs -0.025,P=.002);非网片手术在2011年7月前已轻微下降,此后下降更快但不显著(斜率-0.004 vs -0.022,P=.47)。
  • 住院手术利用率下降52.2%(P=.002),门诊手术利用率上升18.5%(P=.132)。
  • 住院网片手术单次支付从2010年8,315美元增至2013年9,315美元(增幅12.0%,P=.001),住院非网片手术从7,826美元增至9,048美元(增幅15.6%,P=.005);门诊网片手术从4,961美元增至6,981美元(增幅41%,P=.006),门诊非网片手术从3,955美元增至5,149美元(增幅30%,P=.004)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyze utilization of, and payments for, pelvic organ prolapse procedures after the 2011 U.S. Food and Drug Administration (FDA) communication regarding transvaginal mesh. METHODS: This is a retrospective cohort study examining private claims from three insurance providers for inpatient and outpatient prolapse procedures from 2010 to 2013 in the Health Care Cost Institute. Primary outcomes were the change in utilization of prolapse procedures, with and without mesh, before and after the July 2011 FDA communication. Secondary outcomes were the changes in payments and reimbursements for these procedures. Utilization rates and payments were compared using generalized linear models and interrupted time-series analysis. RESULTS: Utilization of prolapse procedures decreased from 12.3 to 9.7 per 10,000 woman-years (P=.027) with a decrease of 30.7% (3.9 in 2010 to 2.7 in 2013, P=.05) in number of mesh procedures and 16.6% (8.4 in 2010 to 7.0 in 2013, P=.011) for nonmesh procedures. Quarterly utilization of mesh procedures was increasing before the FDA communication and then significantly declined after its release (slope=0.024 vs -0.025, P=.002). Nonmesh procedures, however, were already slightly decreasing before July 2011 and continued to decline at a more rapid pace after that time, although not significantly (slope=-0.004 vs -0.022, P=.47). Inpatient utilization decreased 52.2% (P=.002), whereas outpatient utilization increased 18.5% (P=.132). Payments for individual inpatient procedures, with and without mesh, increased by 12.0% ($8,315 in 2010 to $9,315 in 2013, P=.001) and 15.6% ($7,826 in 2010 to $9,048 in 2013, P=.005), respectively, whereas those for outpatient procedures increased by 41% ($4,961 in 2010 to $6,981 in 2013, P=.006) and 30% ($3,955 in 2010 to $5,149 in 2013, P=.004), respectively. CONCLUSION: Use of prolapse surgery declined during the study period. After the 2011 FDA communication regarding transvaginal mesh, there was a significant decrease in the utilization of procedures with mesh but not for those without mesh. A shift toward outpatient surgeries was observed, and payments for both individual inpatient and outpatient cases increased.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Sammarco AG, Swenson CW, Kamdar NS, et al. Rate of Pelvic Organ Prolapse Surgery Among Privately Insured Women in the United States, 2010-2013. Obstet Gynecol. 2018. PMID: 29420405. doi:10.1097/AOG.0000000000002485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。